These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 37265481)

  • 1. Immunotherapy and immunochemotherapy in combating visceral leishmaniasis.
    Yadagiri G; Singh A; Arora K; Mudavath SL
    Front Med (Lausanne); 2023; 10():1096458. PubMed ID: 37265481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative evaluation of efficacy of chemotherapy, immunotherapy and immunochemotherapy in visceral leishmaniasis-an experimental study.
    Joshi J; Malla N; Kaur S
    Parasitol Int; 2014 Aug; 63(4):612-20. PubMed ID: 24747611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokines: Key Determinants of Resistance or Disease Progression in Visceral Leishmaniasis: Opportunities for Novel Diagnostics and Immunotherapy.
    Dayakar A; Chandrasekaran S; Kuchipudi SV; Kalangi SK
    Front Immunol; 2019; 10():670. PubMed ID: 31024534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: Promising Treatments for this Neglected Disease.
    Roatt BM; Aguiar-Soares RD; Coura-Vital W; Ker HG; Moreira Nd; Vitoriano-Souza J; Giunchetti RC; Carneiro CM; Reis AB
    Front Immunol; 2014; 5():272. PubMed ID: 24982655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy and targeted therapies in treatment of visceral leishmaniasis: current status and future prospects.
    Singh OP; Sundar S
    Front Immunol; 2014; 5():296. PubMed ID: 25183962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for visceral leishmaniasis: A trapeze of balancing counteractive forces.
    Mazire PH; Saha B; Roy A
    Int Immunopharmacol; 2022 Sep; 110():108969. PubMed ID: 35738089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Overview of Immunotherapeutic Approaches Against Canine Visceral Leishmaniasis: What Has Been Tested on Dogs and a New Perspective on Improving Treatment Efficacy.
    Gonçalves AAM; Leite JC; Resende LA; Mariano RMDS; Silveira P; Melo-Júnior OAO; Ribeiro HS; de Oliveira DS; Soares DF; Santos TAP; Marques AF; Galdino AS; Martins-Filho OA; Dutra WO; da Silveira-Lemos D; Giunchetti RC
    Front Cell Infect Microbiol; 2019; 9():427. PubMed ID: 31921703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterologous vaccine therapy associated with half course of Miltefosine promote activation of the proinflammatory response with control of splenic parasitism in a hamster model of visceral leishmaniasis.
    Carvalho LM; Ferreira FC; Gusmão MR; Costa AFP; de Brito RCF; Aguiar-Soares RDO; Reis AB; Cardoso JMO; Carneiro CM; Roatt BM
    Curr Res Immunol; 2021; 2():194-201. PubMed ID: 35492387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The preclinical discovery and development of oral miltefosine for the treatment of visceral leishmaniasis: a case history.
    Reimão JQ; Pita Pedro DP; Coelho AC
    Expert Opin Drug Discov; 2020 Jun; 15(6):647-658. PubMed ID: 32202449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leishmania) donovani.
    Guha R; Das S; Ghosh J; Naskar K; Mandala A; Sundar S; Dujardin JC; Roy S
    Vaccine; 2013 Apr; 31(15):1905-15. PubMed ID: 23499564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designing of a Novel Fusion Protein Vaccine Candidate Against Human Visceral Leishmaniasis (VL) Using Immunoinformatics and Structural Approaches.
    Atapour A; Ghalamfarsa F; Naderi S; Hatam G
    Int J Pept Res Ther; 2021; 27(3):1885-1898. PubMed ID: 33935610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leishmaniasis.
    Herwaldt BL
    Lancet; 1999 Oct; 354(9185):1191-9. PubMed ID: 10513726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetically modified live attenuated vaccine: A potential strategy to combat visceral leishmaniasis.
    Pandey SC; Kumar A; Samant M
    Parasite Immunol; 2020 Sep; 42(9):e12732. PubMed ID: 32418227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre- & post-treatment evaluation of immunological features in Indian visceral leishmaniasis (VL) patients with HIV co-infection.
    Sinha PK; Bimal S; Singh SK; Pandey K; Gangopadhyay DN; Bhattacharya SK
    Indian J Med Res; 2006 Mar; 123(3):197-202. PubMed ID: 16778304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parasite Genotype Is a Major Predictor of Mortality from Visceral Leishmaniasis.
    Grace CA; Sousa Carvalho KS; Sousa Lima MI; Costa Silva V; Reis-Cunha JL; Brune MJ; Forrester S; Pedrozo E Silva de Azevedo CM; Costa DL; Speed D; Mottram JC; Jeffares DC; Costa CHN
    mBio; 2022 Dec; 13(6):e0206822. PubMed ID: 36222512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A spotlight on the diagnostic methods of a fatal disease Visceral Leishmaniasis.
    Kumar A; Pandey SC; Samant M
    Parasite Immunol; 2020 Oct; 42(10):e12727. PubMed ID: 32378226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulatory role of Th17 pathway in experimental visceral leishmaniasis.
    Khatonier R; Ahmed G; Sarmah P; Narain K; Khan AM
    Immunobiology; 2021 Nov; 226(6):152148. PubMed ID: 34773853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of growth arrested Leishmania amastigotes: a tool to develop live attenuated vaccine candidates against visceral leishmaniasis.
    Selvapandiyan A; Dey R; Gannavaram S; Solanki S; Salotra P; Nakhasi HL
    Vaccine; 2014 Jun; 32(31):3895-901. PubMed ID: 24837513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metagenomic analysis of taxa associated with Lutzomyia longipalpis, vector of visceral leishmaniasis, using an unbiased high-throughput approach.
    McCarthy CB; Diambra LA; Rivera Pomar RV
    PLoS Negl Trop Dis; 2011 Sep; 5(9):e1304. PubMed ID: 21909446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leishmaniasis in Sudan. Visceral leishmaniasis.
    Zijlstra EE; el-Hassan AM
    Trans R Soc Trop Med Hyg; 2001 Apr; 95 Suppl 1():S27-58. PubMed ID: 11370250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.